Status: Not yet recruiting
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.
Participants needed: 54
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Amphista Therapeutics LtdUpdated: Jul 23, 2026
Eligibility criteria
Participants with relapsed or refractory AML who have failed all available stand... [+5]
Diagnosis of acute promyelocytic leukaemia or chronic myelogenous leukaemia in b... [+16]